Sequenom (Sequenom) EBIT : $-32.9 Mil (TTM As of Jun. 2016)

View and export this data going back to 2000. Start your Free Trial

What is Sequenom EBIT?

Sequenom's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2016 was $-4.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2016 was $-32.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sequenom's annualized ROC % for the quarter that ended in Jun. 2016 was -73.51%. Sequenom's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2016 was -272.99%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sequenom's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2016 was -11.56%.

Sequenom EBIT Historical Data

The historical data trend for Sequenom's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequenom EBIT Chart

Sequenom Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

EBIT

Get a 7-Day Free Trial

-74.21

-114.56

-102.33

-13.86

-7.99

Sequenom Quarterly Data
	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
EBIT	Get a 7-Day Free Trial															-6.97	-7.30	-10.08	-11.30	-4.26

Competitive Comparison of Sequenom's EBIT

For the Biotechnology subindustry, Sequenom's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sequenom's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sequenom's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sequenom's EV-to-EBIT falls into.

Sequenom EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.9 Mil.

Sequenom (NAS:SQNM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sequenom's annualized ROC % for the quarter that ended in Jun. 2016 is calculated as:

	ROC % (Q: Jun. 2016 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2016 )	+	Invested Capital (Q: Jun. 2016 ))	/ count )
=	-17.824 * ( 1 - -0.91% )	/	( (26.544	+	22.393)	/ 2 )
=	-17.9861984	/	24.4685
=	-73.51 %

where

	Invested Capital		(Q: Mar. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	104.616	-	19.601	-	( 66.057	-	max(0, 20.49	-	78.961	+	66.057	))
=	26.544

	Invested Capital		(Q: Jun. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	97.329	-	22.059	-	( 61.328	-	max(0, 22.486	-	75.363	+	61.328	))
=	22.393

Note: The Operating Income data used here is four times the quarterly (Jun. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

Sequenom's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2016 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2016 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2016		Q: Jun. 2016
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-17.04	/	( ( (7.651 + max(-7.275, 0))	+	(4.833 + max(-8.451, 0)) )	/	2 )
=	-17.04	/	( ( 7.651	+	4.833 )	/	2 )
=	-17.04	/	6.242
=	-272.99 %

where Working Capital is:

	Working Capital		(Q: Mar. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(6.95	+	2.994	+	2.96)	-	(19.601	+	0	+	0.578)
=	-7.275

	Working Capital		(Q: Jun. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(7.284	+	4.276	+	2.475)	-	(22.059	+	0	+	0.427)
=	-8.451

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2016) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sequenom's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2016 )
	=	-32.944	/	284.990
	=	-11.56 %

Sequenom EBIT Related Terms

Thank you for viewing the detailed overview of Sequenom's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sequenom (Sequenom) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (NAS:SQNM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sequenom.com

Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.

Executives

Richard A Lerner	director	THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Kenneth F Buechler	director
Charles P Slacik	director	250 S. KRAEMER BLVD, BREA CA 92821
Jeffrey D Linton	officer: Sr VP, GC & Secretary	3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Carolyn Beaver	officer: SVP & CFO	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Benjamin R Miller	director	430 SOUTH SPRING STREET, BURLINGTON NC 27215
William Haas	director
Goldman Myla Lai	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Eberts F Samuel Iii	director, officer: Chairman, President & Sec	22 W FRONTAGE ROAD, NORTHFIELD IL 60093
Glenn A Eisenberg	director, officer: EVP and Treasurer	P O BOX 1017, CHARLOTTE NC 28201-1017
Van Der Vaart Sandra D	director	531 SOUTH SPRING STREET, BURLINGTON NC 27215
David Pendarvis	director	REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Camber Capital Management Lp	10 percent owner	101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
William J Welch	officer: President & CEO	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121